Boundless Bio to Present Preclinical Data on BBI-940 at AACR Annual Meeting 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BOLD?
Source: NASDAQ.COM
- Clinical Data Presentation: Boundless Bio announced it will present preclinical data on its lead therapy BBI-940 at the 2026 American Association for Cancer Research Annual Meeting, targeting advanced or metastatic breast cancer patients, showcasing its potential in cancer treatment.
- FDA Application Approval: In January 2026, the U.S. FDA accepted the Investigational New Drug application for BBI-940, marking a significant advancement in the clinical development of this therapy and potentially accelerating its path to market.
- Mechanism Research Findings: Studies indicate that genetic and pharmacological degradation of Kinesin leads to ecDNA mis-segregation and depletion, thereby reducing the viability of ecDNA+ cancer cells, providing a novel therapeutic strategy for high-risk cancers.
- Strong Financial Position: As of December 31, 2025, Boundless Bio reported cash and cash equivalents totaling $107.6 million, expected to fund operations into the second half of 2028, demonstrating the company's ongoing investment capability in R&D.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BOLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BOLD
Wall Street analysts forecast BOLD stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.600
Low
4.00
Averages
4.00
High
4.00
Current: 1.600
Low
4.00
Averages
4.00
High
4.00
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boundless Bio to Present Preclinical Data on BBI-940 at AACR Annual Meeting 2026
- Clinical Data Presentation: Boundless Bio announced it will present preclinical data on its lead therapy BBI-940 at the 2026 American Association for Cancer Research Annual Meeting, targeting advanced or metastatic breast cancer patients, showcasing its potential in cancer treatment.
- FDA Application Approval: In January 2026, the U.S. FDA accepted the Investigational New Drug application for BBI-940, marking a significant advancement in the clinical development of this therapy and potentially accelerating its path to market.
- Mechanism Research Findings: Studies indicate that genetic and pharmacological degradation of Kinesin leads to ecDNA mis-segregation and depletion, thereby reducing the viability of ecDNA+ cancer cells, providing a novel therapeutic strategy for high-risk cancers.
- Strong Financial Position: As of December 31, 2025, Boundless Bio reported cash and cash equivalents totaling $107.6 million, expected to fund operations into the second half of 2028, demonstrating the company's ongoing investment capability in R&D.
See More
Boundless Bio Presents Preclinical Data for BBI-940 at AACR 2026
- Preclinical Data Presentation: Boundless Bio showcased preclinical data for its lead ecDNA-directed therapy BBI-940 at the 2026 AACR Annual Meeting, indicating its potential as a first-in-class oral selective Kinesin degrader for treating intractable tumors.
- Target Discovery: The research team identified a novel Kinesin target essential for ecDNA segregation and inheritance in cancer cells but non-essential in healthy cells, laying the groundwork for developing new therapies targeting ecDNA-positive tumors.
- Clinical Trial Progress: BBI-940 is currently undergoing the first-in-human Phase 1 KOMODO-1 clinical trial for patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR, with preliminary results showing promising antitumor activity across multiple tumor types.
- Market Potential: With 14% to 17% of cancer patients exhibiting ecDNA amplification, the development of BBI-940 not only addresses significant unmet medical needs but also positions Boundless Bio for a strategic advantage in the competitive oncology market.
See More
Boundless Bio Q4 Earnings Miss Expectations
- Earnings Performance: Boundless Bio reported a Q4 GAAP EPS of -$0.58, missing expectations by $0.12, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $107.6 million in cash, cash equivalents, and short-term investments, reflecting a solid liquidity position in the short term, though long-term sustainability remains a concern.
- Operational Funding Outlook: The company expects its cash reserves to fund operations into the second half of 2028, coinciding with the anticipated initial clinical proof-of-concept readout from KOMODO-1, which is crucial for future growth prospects.
- Market Reaction Expectations: Given the earnings miss, investors may express concerns regarding the company's future clinical trials and cash utilization plans, potentially impacting stock performance and market confidence.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
See More
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
See More
Boundless Bio to Present Preclinical Data on BBI-940 at AACR Annual Meeting 2026
- Clinical Data Presentation: Boundless Bio announced it will present preclinical data on its lead therapy BBI-940 at the 2026 American Association for Cancer Research Annual Meeting, targeting advanced or metastatic breast cancer patients, showcasing its potential in cancer treatment.
- FDA Application Approval: In January 2026, the U.S. FDA accepted the Investigational New Drug application for BBI-940, marking a significant advancement in the clinical development of this therapy and potentially accelerating its path to market.
- Mechanism Research Findings: Studies indicate that genetic and pharmacological degradation of Kinesin leads to ecDNA mis-segregation and depletion, thereby reducing the viability of ecDNA+ cancer cells, providing a novel therapeutic strategy for high-risk cancers.
- Strong Financial Position: As of December 31, 2025, Boundless Bio reported cash and cash equivalents totaling $107.6 million, expected to fund operations into the second half of 2028, demonstrating the company's ongoing investment capability in R&D.
See More
Boundless Bio Presents Preclinical Data for BBI-940 at AACR 2026
- Preclinical Data Presentation: Boundless Bio showcased preclinical data for its lead ecDNA-directed therapy BBI-940 at the 2026 AACR Annual Meeting, indicating its potential as a first-in-class oral selective Kinesin degrader for treating intractable tumors.
- Target Discovery: The research team identified a novel Kinesin target essential for ecDNA segregation and inheritance in cancer cells but non-essential in healthy cells, laying the groundwork for developing new therapies targeting ecDNA-positive tumors.
- Clinical Trial Progress: BBI-940 is currently undergoing the first-in-human Phase 1 KOMODO-1 clinical trial for patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR, with preliminary results showing promising antitumor activity across multiple tumor types.
- Market Potential: With 14% to 17% of cancer patients exhibiting ecDNA amplification, the development of BBI-940 not only addresses significant unmet medical needs but also positions Boundless Bio for a strategic advantage in the competitive oncology market.
See More
Boundless Bio Q4 Earnings Miss Expectations
- Earnings Performance: Boundless Bio reported a Q4 GAAP EPS of -$0.58, missing expectations by $0.12, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $107.6 million in cash, cash equivalents, and short-term investments, reflecting a solid liquidity position in the short term, though long-term sustainability remains a concern.
- Operational Funding Outlook: The company expects its cash reserves to fund operations into the second half of 2028, coinciding with the anticipated initial clinical proof-of-concept readout from KOMODO-1, which is crucial for future growth prospects.
- Market Reaction Expectations: Given the earnings miss, investors may express concerns regarding the company's future clinical trials and cash utilization plans, potentially impacting stock performance and market confidence.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
See More
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
See More
